HEALTH-RELATED QUALITY OF LIFE IN NMIBC PATIENTS WITH VARIOUS TREATMENT MODALITIES: A SYSTEMATIC REVIEW
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Introduction: Non-muscle-invasive bladder cancer (NMIBC) is one of the most common urological malignancies, accounting for approximately 75% of newly diagnosed bladder cancer cases. Intravesical instillation therapy is widely utilized as an integral part of NMIBC treatment. Objective: This systematic review aims to synthesize current evidence on the impact of various intravesical instillation therapies, including BCG, gemcitabine, and epirubicin, as well as TURBT, on the HRQoL of NMIBC patients. Material & Methods: The search was carried out using the Google Scholar and PubMed search engines. Search keywords "Quality of life", "non-muscle-invasive-bladder-cancer", and "intravesical instillation". Results: Total of 711 articles were screened by keywords and literature reading. The articles continued screen for the eligibility with exclusion criteria. A total of 8 articles is continued for reading and reviewing process. Conclusion: Studies consistently show that gemcitabine/docetaxel regimens can improve QoL with fewer side effects compared to BCG. TURBT combined with intravesical therapies has demonstrated stable or improved QoL over time, reinforcing its role as a preferred treatment. The use of QoL tools, such as the EORTC QLQ-NMIBC24 and CAVICAVENMI, helps to capture patient-reported outcomes and inform the development of tailored interventions. Keywords: Quality of life, NMIBC, intravesical instillation.
##plugins.themes.bootstrap3.article.details##
Quality of life, NMIBC, intravesical instillation.
Yuen JW, Wu RW, Ching SS, Ng CF (2022) Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review. Int J Environ Res Public Health. 19(17). doi:10.3390/ijerph191710825
Pareek T, Parmar K, Sharma AP, Kumar S (2022) Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study. Urol Int.;106(8):784-790. doi:10.1159/000524098
Wang EY, Armas-Phan M, Meng M V., Loeb S, Kenfield SA, Porten SP (2023) Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life. Bladder Cancer.;9(4):323-326. doi:10.3233/BLC-230061
Cassell A, Yunusa B, Jalloh M, et al (2019) Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa. World J Oncol.;10(3):123-131. doi:10.14740/wjon1210
Wang W, Chen Y, Gu J (2024) Effectiveness of integrated nursing interventions in enhancing patient outcomes during postoperative intravesical instillation for non-muscle invasive bladder cancer: A comparative study. Medicine (United States).;103(11):E36871. doi:10.1097/MD.0000000000036871
Trifanescu OG, Gales LN, Paun MA, et al (2023) Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option? Medicina (Lithuania).;59(1). doi:10.3390/medicina59010050
Matulewicz RS, Steinberg GD (2020) Non-Muscle-Invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies.:
Roumiguié M, Black PC (2022) Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non–muscle-invasive bladder cancer: Pro. Eur Urol Focus.;8(4):1117-1120. doi:10.1016/j.euf.2021.07.018
Claps F, Pavan N, Ongaro L, et al (2023) BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets. Int J Mol Sci;24(16). doi:10.3390/ijms241612596
Barry J (1994) Transurethral clot evaluation from a bladder with a catheter irrigating syringe. J Urol. 1994;151(689):689. doi:https://doi.org/10.1016/s0022-5347(17)35049-8
Wang Y, Tang J, Yang C, et al (2024) Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer. Chinese Journal of Pharmacovigilance; 21(9):1044-1050. doi:10.19803/j.1672-8629.20230543
Westhoff E. Lifestyle and Non-Muscle-Invasive Bladder Cancer: Prognosis, Quality of Life, and Patients’ Awareness.
Rentsch CA, Thalmann GN, Lucca I, et al (2022) A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. Eur Urol Oncol.;5(2):195-202. doi:10.1016/j.euo.2021.12.006
Van Straten CGJI, Caris C, Grimm MO, et al (2023) Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial. Eur Urol Open Sci; 56:15-24. doi:10.1016/j.euros.2023.08.004
Vaioulis A, Bonotis K, Perivoliotis K, et al (2021) Quality of Life and Anxiety in Patients with First Diagnosed Non-Muscle Invasive Bladder Cancer Who Receive Adjuvant Bladder Therapy. Bladder Cancer;7(3):297-306. doi:10.3233/BLC-201524
Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, et al (2023) Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol.;6(1):58-66. doi:10.1016/j.euo.2022.10.008
Mostafid AH, Porta N, Cresswell J, et al (2020) CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int;125(6):817-826. doi:10.1111/bju.15038
Rogers Z, Glaser A, Catto JWF, et al (2024) Health-related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year. BJU Int;133(4):460-473. doi:10.1111/bju.16242
Zeng N, Xu MY, Sun JX, et al (2023) Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette–Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis. Front Oncol.;13. doi:10.3389/fonc.2023.1164932
Jung A, Nielsen ME, Crandell JL, et al (2019) Quality of life in non-muscle-invasive bladder cancer survivors: A systematic review. Cancer Nurs.;42(3):E21-E33. doi:10.1097/NCC.0000000000000606
Ucer O, Temeltas G, Gumus B, Muezzinoglu T (2021) Comparison of pain, quality of life, lower urinary tract symptoms and sexual function between flexible and rigid cystoscopy in follow-up male patients with non muscle invasive bladder cancer: A randomized controlled cross section single blind study. Int J Clin Pract.;75(4). doi:10.1111/ijcp.13853
Ward K, Kitchen MO, Mathias SJ, Khanim FL, Bryan RT (2022) Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning. Front Surg;9. doi:10.3389/fsurg.2022.912438
Han MA, Maisch P, Jung JH, et al (2021) Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged cochrane review. Investig Clin Urol.;62(6):623-630. doi:10.4111/icu.20210265
Zhou Q, Chen X, Chen Q, Hao L (2023) Factors Influencing Quality of Life and Functional Outcomes in Patients With Bladder Cancer. Cancer Control.;30. doi:10.1177/10732748231212353
Brassart C, Coutte A, Wallet J, et al (2024) Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study. Cancer/Radiotherapie. Published online December 1,. doi:10.1016/j.canrad.2024.05.005
Park J, Choi YD, Lee K, et al (2022) Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis. Asia Pac J Oncol Nurs.;9(6). doi:10.1016/j.apjon.2022.04.002